Repeated CXL safe and effective for progressive keratoconus

Article

Because the disease is vision-threatening, the investigators retrospectively reviewed the demographic, clinical, and surgical data from the cases of patients who required additional CXL.

Image credit: © mik_cz - stock.adobe.com

Epithelial-off CXL can stabilize keratoconus, but the disease can continue to progress. (Image credit: Adobe Stock/mik_cz)

Israeli investigators reported that after the initial collagen crosslinking (CXL) for progressive keratoconus fails, the procedure can be repeated because it is safe and efficacious,1 according to lead author Ofri Vorobichik Berar, MD, and colleagues from the Department of Ophthalmology, Goldschleger Eye Institute, Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer, Israel.

Epithelial-off CXL can stabilize keratoconus, but the disease can continue to progress. Because the disease is vision-threatening, the investigators retrospectively reviewed the demographic, clinical, and surgical data from the cases of patients who required additional CXL.

The researchers identified 9 patients (10 eyes) with progressive keratoconus after an initial CXL procedure. The mean patient age when keratoconus was diagnosed was 20.2 years. The patients underwent a repeat CXL procedure and were followed for a mean of 2.1 years.

The data showed the mean best-corrected visual acuity remained stable during follow-up.

They reported that the mean baseline Kmax was 60.4 diopters (D). Before the second CXL procedure, the, Kmax had progressed significantly (P = 0.018) to 62.2 D; at the last follow-up, examination, the Kmax decreased significantly (P = 0.037) to 60.3 D. The mean baseline minimal pachymetry was 464.0 microns. Before the repeated CXL, the minimal pachymetry was significantly lower (P = 0.018), and after the repeated CXL procedure, the minimal pachymetry was stable (P = 0.2). No intraoperative or postoperative complications were noted.

The study concluded, “Repeated CXL is a safe and effective treatment option when failure of the initial CXL is diagnosed, even in young patients. This procedure may prevent visual deterioration and a potential need for keratoplasty.”

Reference
1. Vorobichik Berar O, Rotenberg M, Berger Y, et al. Safety and efficacy of repeated corneal collagen crosslinking in progressive keratoconus. Cornea. 2023;42:423-8; DOI: 10.1097/ICO.0000000000003165
Recent Videos
Optometrists local to the Los Angeles area overview their efforts to continue providing support to patients affected by January's wildfires.
Brianna Rhue, OD, FAAO, FSLS, reviewed key takeaways from The Future of Myopia Management: Perspectives from Leading Experts talk from SECO 2025.
Dr. Nate Lighthizer shares key takeaways from the SECO Showcase on anterior segment technology and full laser certification course offered at SECO.
Robert L. Stamper, MD, overviews his optometric track talk titled Objective Perimetry - Can you see it? at this year's Glaucoma 360 meeting.
Three EnVision Summit faculty members weigh in on the importance of comanagement in glaucoma management, where artificial intelligence will lead eye care, and what hopes are on the horizon for corneal ectasia treatments.
Yvonne Ou, MD, outlined lifestyle modifications for glaucoma management that have proven beneficial, including yoga and cycling.
Robert L. Stamper, MD, weighs in on what he think more optometrists should know about glaucoma and current misconceptions concerning glaucoma testing.
John Berdahl, MD, overviews the new FYXS Ocular Pressure Adjusting Pump and HERCULES trial at the Glaucoma 360 meeting.
Ashley Wallace Tucker, OD, FAAO, FSLS, Dipl ABO, weighs in on what's on the horizon for pediatric myopia management, and provides some tips for diving into scleral lens fitting.
Shan Lin, MD, outlines a new generation of minimally invasive glaucoma surgeries (MIGS) at Glaucoma 360.
© 2025 MJH Life Sciences

All rights reserved.